A phase II study of combined VEGF inhibitor (bevacizumab sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109 (Q37166383)
Jump to navigation
Jump to search
scientific article published on 28 June 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II study of combined VEGF inhibitor (bevacizumab sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109 |
scientific article published on 28 June 2013 |
Statements
1 reference
A phase II study of combined VEGF inhibitor (bevacizumab sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109 (English)
1 reference
Kathy D Miller
1 reference
Lida A Mina
1 reference
Menggang Yu
1 reference
Cynthia Johnson
1 reference
Cyndi Burkhardt
1 reference
Robin Zon
1 reference
28 June 2013
1 reference
1 reference
1307-1310
1 reference
1 October 2013
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference